Kala Bio (KALA) Total Liabilities (2016 - 2026)
Kala Bio's (KALA) quarterly Total Liabilities came in at $1.5 million in Q2 2026, down 96.08% year-over-year from $39.3 million in Q2 2025, and down 1.22% quarter-over-quarter from $1.6 million in Q1 2026.
Analysis
Kala Bio (KALA) Total Liabilities (2016 - 2026) Analysis & Trends
Kala Bio has disclosed Total Liabilities across 11 years of filings, most recently posting $1.5 million for Q2 2026.
- In Q2 2026, Total Liabilities fell 96.08% year-over-year to $1.5 million; the TTM figure through Jun 2026 stood at $1.5 million (down 96.08% YoY), while the FY2025 annual figure was $2.5 million, down 94.22% from the prior year.
- Total Liabilities came in at $1.5 million for Q2 2026 at Kala Bio, down from $1.6 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $116.9 million in Q1 2022 to a low of $1.5 million in Q2 2026.
- Average Total Liabilities over 5 years is $49.4 million, with a median of $47.6 million recorded in 2024.
- Year-over-year, Total Liabilities retreated 2.28% in 2024 and slumped 96.34% in 2026.
- Over 5 years, Total Liabilities stood at $67.8 million in 2022, then dropped by 28.6% to $48.4 million in 2023, then decreased by 10.93% to $43.2 million in 2024, then slumped by 94.22% to $2.5 million in 2025, then plunged by 38.33% to $1.5 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $1.5 million in Q2 2026, $1.6 million in Q1 2026, and $2.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.70 Bn | 192.71 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 180.18 Bn | 177.00 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 60.60 Bn | 55.42 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 53.81 Bn | 48.67 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 33.46 Bn | 30.15 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.82 Bn | 30.54 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 29.10 Bn | 29.10 Bn | 1.16 Mn | 384.62 Mn |
| 10 | Kala Bio | 8.48 Mn | 8.48 Mn | - | 1.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.54 Mn |
| Mar 31, 2026 | 1.56 Mn |
| Dec 31, 2025 | 2.49 Mn |
| Sep 30, 2025 | 33.69 Mn |
| Jun 30, 2025 | 39.26 Mn |
| Mar 31, 2025 | 42.54 Mn |
| Dec 31, 2024 | 43.15 Mn |
| Sep 30, 2024 | 47.22 Mn |
| Jun 30, 2024 | 47.89 Mn |
| Mar 31, 2024 | 46.37 Mn |
| Dec 31, 2023 | 48.45 Mn |
| Sep 30, 2023 | 49.90 Mn |
| Jun 30, 2023 | 49.01 Mn |
| Mar 31, 2023 | 48.77 Mn |
| Dec 31, 2022 | 67.85 Mn |
| Sep 30, 2022 | 86.67 Mn |
| Jun 30, 2022 | 116.53 Mn |
| Mar 31, 2022 | 116.86 Mn |
| Dec 31, 2021 | 122.62 Mn |
| Sep 30, 2021 | 132.35 Mn |